On November 5, Twist Bioscience Corp fell 5.15% in Pre-Market Trading, trading at $133.01/share, with turnover of $672,200.
The clearest backdrop is that the company is approaching its November 12 earnings release, while the market continues digesting earlier catalysts tied to AI drug discovery demand, the Lilly TuneLab collaboration, and recently initiated neutral-to-hold analyst coverage.
Consensus expectations point to quarterly revenue of about $123 million, up 25.96% year over year, with adjusted EPS expected at negative $0.37 and loss-narrowing trends continuing. Earlier disclosures also highlighted a major AIDD-related order trajectory, including discussion that AI drug discovery contributed about $25 million of order growth in a prior fiscal year and could scale further, while the September agreement with Lilly TuneLab focused on providing antibody characterization data services for AI/ML-enabled antibody discovery. Jefferies initiated with Hold and a $150 target, while UBS maintained a Neutral view with a $144 target. With no materially new catalyst disclosed in the latest window, recent volatility appears linked to continued repositioning ahead of results.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments